Clinical Trial Update: Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the histone deacetylase inhibitor suberoylanilide hydroxamic acid (vorinostat) in patients with metastatic and/or locally advanced or r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Insular Thyroid Carcinoma
• Medullary Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Insular Thyroid Cancer, Recurrent Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-08-11